Table 3.
Univariate and multivariate Cox regression analysis of characteristics and prognosis index in HCC.
| Characteristics | Patients | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| HR 1 (95% CI) 2 | p–Value | HR (95% CI) | p–Value | ||
| Gender (male/female) | 255/122 | 0.758 (0.498–1.154) | 0.196 | 0.763 (0.482–1.208) | 0.249 |
| Age (≤ 65 vs. > 65) | 235/141 | 0.666 (0.441––1.007) | 0.054 | 0.729 (0.463–1.145) | 0.17 |
| Tumor (T3–T4/T1–T2) | 94/280 | 1.794 (1.146–2.808) | 0.011 | 0.715 (0.086–5.919) | 0.756 |
| Pathologic stage (III–IV/I–II) | 91/262 | 1.483 (0.906–2.427) | 0.117 | 0.744 (0.298–1.856) | 0.526 |
| BMI 3 (≥ 25 vs. <25) | 161/180 | 0.906 (0.577–1.423) | 0.669 | ||
| Adjacent_hepatic_tissue_inflammation (no/yes) | 119/120 | 1.128 (0.662–1.923) | 0.657 | ||
| Virus 4 (no/yes) | 211/166 | 0.649 (0.428–0.985) | 0.042 | ||
| Fibrosis (no/yes) | 76/142 | 0.813 (0.474–1.397) | 0.454 | ||
| Radiation therapy (no/yes) | 243/4 | 2.127 (0.29–15.622) | 0.458 | ||
| Relative_family_cancer_history (no/yes) | 212/114 | 1.795 (1.16–2.779) | 0.009 | ||
| Pharmaceutical_therapy (no/yes) | 103/26 | 2.189 (0.951–5.04) | 0.066 | ||
| New tumor event after initial treatment (no/yes) |
149/142 | 1.592 (0.877–2.89) | 0.126 | 0.654 (0.179–2.382) | 0.519 |
| Person neoplasm cancer status (with tumor/tumor free) |
123/157 | 2.208 (1.224–3.983) | 0.009 | 2.816 (0.774–10.245) | 0.116 |
| PI (High–risk/Low–risk) | 174/174 | 1.838 (1.177–2.87) | 0.007 | 2.469 (1.238–4.923) | 0.01 |
1 hazard ratio; 2 95% confidence interval; 3 body mass index; 4 HBV or HCV infection.